Journal of Clinical Oncology
Articles in this Issue
Patterns in male and female breast cancer care: A comparative analysis of stage at presentation, treatment, and survival in the Veterans Health Administration.
538 Background: Male breast cancer (MBC) is a rare disease that is often managed using treatment protocols derived from female breast cancer (FBC). Given...
Benefit of adding Cureety remote patient monitoring (RPM) to usual care during injectable anticancer treatment: The OPTIMACURE multicentric French prospective randomized study.
11017 Background: In routine care, assessing whether a patient can safely be administered an injectable anticancer treatment requires the review of blood...
Analyzing fatigue as a common adverse effect in patients treated with immune checkpoint inhibitors.
e23190 Background: The discovery of Immune checkpoint inhibitors has been a big step in oncology due to its role in the di...
Phase I trial of capecitabine with cemiplimab in patients with hormone receptor–positive metastatic breast cancer.
e13082 Background: Immunotherapy has been used in hormone receptor positive (HR+) HER2 negative metastatic breast cancer (MBC) and has shown modest clinic...
Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC).
3002 Background: iza-bren is a first-in-class ADC comprised of an EGFR x HER3 bispecific antibody conjugated to a novel topo-I inhibitor payload (Ed-04) v...
Real-world outcomes of neoadjuvant immunotherapy for mismatch repair-deficient colorectal cancer: A single center experience in Russia.
e15647 Background: Microsatellite instability (MSI) and mismatch repair deficiency (dMMR) are key biomarkers predicting positive responses to immunotherap...
Impact of postmastectomy radiotherapy on health-related quality of life and safety in breast cancer patients undergoing breast reconstruction: A multi-center cross-sectional study (Reborn-02).
574 Background: Postmastectomy radiotherapy (PMRT) is the standard treatment for improving the prognosis of patients with high-risk breast cancer. Expande...
Survival outcomes in rectal cancer with ypTNM vs pTNM staging after neoadjuvant therapy.
e15694 Background: The TNM classification at pathological evaluation determines prognosis following cancer treatment. For rectal cancer patients who under...
HER2 positive/hormone positive vs HER2 positive/hormone negative breast cancer: Clinical presentation, prognosis, and time to relapse—A retrospective cohort study.
e13017 Background: Breast cancer is among the most common malignancies globally, placing a substantial strain on healthcare systems and affecting patient...
Broad implementation of AI for lymph node assessment: Insights from a head-to-head comparison of two applications.
e13679 Background: Lymph node (LN) assessment is pivotal for guiding treatment in breast cancer (BC), head- and neck cancer (HNC) and melanoma, yet it imp...
Climate change and cancer: An ecological evaluation of climate risks for cancer survivors.
11093 Background: Changes in climate patterns will influence the frequency and severity of extreme weather events, leading to increased disasters (e.g., f...
Initial experience of preoperative gemcitabine and cisplatin plus durvalumab followed by resection for high-risk biliary tract cancer.
e16329 Background: Althoughgemcitabine and cisplatin plus durvalumab (GC+D) are standard of care for metastatic biliary tract cancer (BTC), the regimen’s...
Early adverse symptoms to predict response to treatment among patients in the I-SPY trial.
610 Background: The adverse event (AE) landscape in oncology is changing due to the introduction of immunotherapy and antibody drug conjugates. These AEs...
NivoReach: Integrated study to demonstrate similarity of JPB898 to reference nivolumab in combination with ipilimumab in patients with advanced melanoma.
TPS9595 Background: JPB898 is being developed as a biosimilar to reference nivolumab. Analytical and functional in vitro similarity of JPB898 to reference...
IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation and dose-expansion study.
e13061 Background: IMM27M is a humanized Fc-engineered IgG1 CTLA-4 monoclonal antibody with enhanced ADCC. In pre-clinical models, IMM27M enhanced immune...
Pucotenlimab in high microsatellite instability/mismatch repair–defificient (MSI-H/ dMMR) solid tumors: Results update from a multicenter, phase II, open-label study.
e14589 Background: Pucotenlimab, an anti-PD-1 antibody, demonstrated robust antitumor activity in patients (pts) with MSI-H/dMMR, based on findings from t...
15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS.
505 Background: Long-term follow-up of the SOFT and TEXT randomized trials has shown persistent reduction of recurrence fr...
Safety and efficacy of OR502, an antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2), ± cemiplimab in patients with advanced solid tumors from a phase 1 study.
2524 Background: OR502 is a humanized IgG1 antibody that targets LILRB2, blocking its binding to HLA ligands A, B and G. OR502 prevents and reverses myelo...
A phase 1 study to evaluate the safety and tolerability of BXQ-350, a novel sphingolipid metabolism modulator, in pediatric diffuse intrinsic pontine glioma and diffuse midline glioma.
e14044 Background: Diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) are aggressive brain tumors in children that have a poor progn...
Development of a prognostic score for stage IV NSCLC using advance machine learning algorithms: An international comparative study across South Korea, US, and France.
e20615 Background: Patients with Stage IV NSCLC have a poor prognosis, with approximately 25-30% succumbing to the disease within the first three months....
Impact of protein-energy malnutrition on mortality, length of stay, and hospitalization costs in patients with heart failure and a history of cancer.
e13799 Background: Protein-energy malnutrition (PEM) is a common comorbidity in patients with a history of cancer and significantly worsens outcomes in th...
Bridging the gap: Cancer care outcomes and social determinants of health in the Rio Grande Valley (RGV), a south Texas border region—A county-level analysis (2017-2021).
e13801 Background: The Rio Grande Valley (RGV), a region in South Texas along the U.S.-Mexico border encompassing Cameron, Hidalgo, Starr, and Willacy cou...
A multicenter, randomized, controlled, open-label trial to determine the optimal duration of steroid therapy for mild pneumonitis associated with immune checkpoint inhibitors.
12006 Background: The optimal duration of corticosteroid therapy for pneumonitis associated with immune checkpoint inhibitors is clinically relevant. Seve...
Germline pathogenic variants in <i>BRCA1-,</i> <i>BRCA2-</i> , and <i>PALB2-</i> genes among Ethiopian young women and men diagnosed with breast cancer.
10567 Background: Breast cancer incidence is rapidly increasing in low-and-middle-income countries (LMICs), where access to care is limited and survival o...
Efficacy and safety of immune checkpoint inhibitors in Child-Pugh B and C hepatocellular carcinoma: Impact of treatment line, local therapy and bevacizumab combination.
e16175 Background: The safety and efficacy of immune checkpoint inhibitors (ICI) in Child-Pugh (CP)-B and CP-C hepatocellular carcinoma (HCC) patients rem...